@inbook{6d880a07c4e64062aa8b8633823f03a6,
title = "Off-the-Shelf CAR-T",
abstract = "The FDA has approved CAR-T cell therapy for the treatment of B cell malignancies. Despite the clinical success of CD19 targeted CAR-T, several barriers limit the wider adoption of CAR-based therapies as viable long-term cancer therapies. Many of the barriers that limit the routine use of CAR-T cell therapies stem from utilizing autologous patient T cells as the starting material to generate CAR-T. Here we will describe the limitations of autologous CAR-T, the advantages and hurdles of allogeneic donor CAR-T, the learnings from clinical trials using allogeneic CART19 and discuss the future direction of the field.",
keywords = "Allogeneic CAR-T, Allogeneic cellular therapy, CAR-T, CRISPR/Cas9, Genetically edited donor derived CAR-T, Off the shelf CAR-T, TALEN, TCRab deleted T cells, TRAC, UCART123, UCART19, UCART7, Universal CAR-T, β2-microglobulin (B2M)",
author = "Matthew Cooper and Giorgio Ottaviano and DiPersio, {John F.} and Waseem Qasim",
note = "Publisher Copyright: {\textcopyright} 2022, Springer Nature Switzerland AG.",
year = "2022",
doi = "10.1007/978-3-030-87849-8_7",
language = "English",
series = "Cancer Drug Discovery and Development",
publisher = "Humana Press Inc.",
pages = "109--120",
booktitle = "Cancer Drug Discovery and Development",
}